Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
PRISMA Study (Prospective, Randomized Trial on Intensive Self-Monitoring Blood Glucose Management Added Value in Non-Insulin Treated Type 2 Diabetes Mellitus Patients)
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- Device: Accu-Chek Aviva Meter
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2016-03-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1000
- Registration Number
- NCT00643474
A Study of Avastin (Bevacizumab) in Combination With Standard Chemotherapy in Children and Adolescents With Sarcoma.
- Conditions
- Sarcoma
- Interventions
- Drug: Standard chemotherapy
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2019-10-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 154
- Registration Number
- NCT00643565
- Locations
- 🇧🇪
Cliniques Universitaires St-Luc, Bruxelles, Belgium
🇧🇪Hôpital Enfants Reine Fabiola, Bruxelles, Belgium
🇧🇪UZ Gent, Gent, Belgium
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Drug: PlaceboDrug: Non-steroidal anti-inflammatory drugs (NSAIDs)Drug: corticosteroids
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 112
- Registration Number
- NCT00642460
A Study of Metronidazole Cream in the Prevention and Treatment of Tarceva (Erlotinib)-Associated Rash
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2016-05-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 34
- Registration Number
- NCT00642473
A Study of Subcutaneous C.E.R.A. for the Maintenance of Hemoglobin Levels in Participants With Chronic Renal Anemia Not on Dialysis.
- Conditions
- Anemia
- Interventions
- Drug: methoxy polyethylene glycol-epoetin beta [C.E.R.A.]
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT00642304
- Locations
- 🇳🇱
Albert Schweitzer Ziekenhuis; Inwendige Geneeskunde, Dordrecht, Netherlands
🇳🇱Nij Smellinghe Ziekenhuis; Inwendige Geneeskunde, Drachten, Netherlands
🇳🇱Oosterscheldeziekenhuis, Goes, Netherlands
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 317
- Registration Number
- NCT00642941
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸UCLA School Of Medicine Mattel's Children's Hospital At UCLA; Division Of Hematology-Oncology, Los Angeles, California, United States
🇺🇸Pennsylvania Oncology Hema Asc, Philadelphia, Pennsylvania, United States
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 41
- Registration Number
- NCT00642603
A Genetic Substudy Associated With the Avastin (Bevacizumab) Study MO19390 in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- Drug: Standard chemotherapy
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 3
- Registration Number
- NCT00642824
A Study of Subcutaneous Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2017-07-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 35
- Registration Number
- NCT00642668
- Locations
- 🇧🇪
ZNA Stuivenberg, Antwerpen, Belgium
🇧🇪ZNA Middelheim, Antwerpen, Belgium
🇧🇪CH EpiCURA Site Hornu, Hornu, Belgium
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer.
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2022-12-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 214
- Registration Number
- NCT00642577